Urinary Tract Infection (UTI) Treatment Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI2008
Urinary Tract Infection Treatment Market share is slated to witness a major upsurge over 2021-2027, considering the rising prevalence of UTIs among females of reproductive age group (15-44 years), coupled with other risk factors including the use of contraceptive diaphragms, menopause, and urinary tract abnormalities. The urinary tract infection is one of the most common clinical bacterial infections in pregnant women. A UTI is an infection in the urinary system including the urethra, bladder, ureters, and kidneys, with most infections involving the lower urinary tract. This form of infection typically occurs when bacteria enter the urinary tract via the urethra and later multiply in the bladder.
Strong awareness about the association of obesity and diabetes with bladder dysfunction, alongside the rapid deployment of innovative technology including nanotechnology for efficient UTI treatment, are among the key trends stimulating the overall market outlook. T2D (type 2 diabetes) patients, for example, are at increased risk of recurrent UTI as a result of uncontrolled glycemia. Studies suggest that the prevalence of the disease among these patients was 39.6% in 2020.
However, limitations in terms of product costs and other side effects associated with common UTI therapies like fluoroquinolones, such as variations in blood sugar levels and central nervous system problems such as anxiety, seizures, and insomnia may impede urinary tract infection treatment market expansion to some extent during the forecast timeframe.
Regionally, the North America urinary tract infection treatment market is set to depict a strong growth rate through 2027, owing to the mounting incidences of diabetes and other chronic conditions and the subsequent increase in the UTI patient pool, especially in the U.S. According to the Centers for Disease Control & Prevention, more than 34 million people in America are diagnosed with diabetes, consisting of over 11% of the U.S. population, leading to higher susceptibility to infections like UTIs.
Prominent players operating in the urinary tract infection treatment market include Depomed (Assertio), Forest Laboratories, Actavis (Teva Pharmaceuticals), Cardima, Biotronik, AtriCure , CardioFocus, St. Jude Medical, Biosense Webster, Emcure Pharmaceuticals, GlaxoSmithKline, Bayer, Johnson & Johnson, Cipla, Pfizer, and Roche, among others. These companies are implementing varied strategies including innovative product launches and R&D to drive their business portfolio across the global market.
For example, in September 2020, CARB-X announced an investment of over $7.51 million in GlaxoSmithKline, with an aim to help develop GSK3882347, an orally bioavailable small molecule drug, for the treatment and prevention of recurrent UTIs caused by E. coli bacteria. Meanwhile, GlaxoSmithKline commenced the first patient dosing of gepotidacin, a new chemical class of antibiotics known as triazaacenaphthylene bacterial topoisomerase inhibitors, in October 2019, in order to transform the treatment landscape of patients with urogenital gonorrhea and uncomplicated urinary tract infection.
Declining Primary Care Services Delivery Amid COVID-19 & its Impact on Urinary Tract Infection Treatment Market Trends:
The unprecedented rise in the number of coronavirus-infected patients had resulted in a drop in the access to other primary care services and a considerable drop in non-COVID-19-related diagnoses, including urinary tract infection. The weekly rate of the diagnosis of UTI slightly declined during 2020, which may have created roadblocks to the growth of the industry over the past few months.
However, various researches have been conducted to identify the changes in the lower urinary tract symptoms among the COVID-19-infected patients. As per the International Prostate Symptom Score of these patients, the elderly patients recorded high lower urinary tract symptoms scores. These significant study results may raise awareness about the potential occurrence of UTI as a symptom of the coronavirus disease and in turn, boost the urinary tract infection diagnosis rate in years to come.
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability